糖酵解对糖尿病及其并发症影响的研究进展
Research Progress on the Impact of Glycolysis on Diabetes and Its Complications
DOI: 10.12677/acm.2025.1541325, PDF,   
作者: 朱妍霖, 周 洁*：重庆医科大学附属口腔医院正畸科，重庆
关键词: 糖尿病；糖尿病并发症；糖酵解；靶向治疗；Diabetes Mellitus； Diabetic Complications； Glycolysis； Targeted Therapy
摘要: 糖尿病(Diabetes Mellitus, DM)是全球高发的代谢性疾病，严重影响患者的生活质量并导致了一系列并发症。糖酵解作为细胞主要的能量生产途径之一，与DM及其并发症的发生和发展密切相关。近年来，糖酵解在DM中的研究取得了重要进展，研究表明糖酵解途径中关键酶的异常表达可能是DM及其并发症的核心病理机制之一。糖酵解的异常不仅破坏了能量代谢的平衡，还可能通过毒性代谢产物的积累加剧糖尿病肾病(DN)、糖尿病心肌病(DCM)、糖尿病视网膜病变(DR)、糖尿病神经病变(DPN)、糖尿病脑血管病(DCVD)等并发症的进展。靶向糖酵解关键酶的治疗策略，展现出对DM及其并发症治疗的巨大潜力，并为新的治疗方法提供了理论依据。
Abstract: Diabetes mellitus (DM) is a globally prevalent metabolic disorder that significantly affects patients’ quality of life and leads to various complications. As one of the primary energy-producing pathways in cells, glycolysis is closely associated with the onset and progression of DM and its complications. In recent years, substantial progress has been made in understanding the role of glycolysis in DM. Studies have demonstrated that abnormal expression of key enzymes in the glycolytic pathway may be a fundamental pathological mechanism underlying DM and its complications. Dysregulated glycolysis not only disrupts energy metabolism homeostasis but also contributes to the accumulation of toxic metabolic byproducts, thereby exacerbating diabetic nephropathy (DN), diabetic cardiomyopathy (DCM), diabetic retinopathy (DR), diabetic peripheral neuropathy (DPN), and diabetic cerebrovascular disease (DCVD). Therapeutic strategies targeting key glycolytic enzymes have shown great potential in the treatment of DM and its complications, providing a theoretical basis for novel therapeutic approaches.
文章引用：朱妍霖, 周洁. 糖酵解对糖尿病及其并发症影响的研究进展[J]. 临床医学进展, 2025, 15(4): 3519-3529. https://doi.org/10.12677/acm.2025.1541325

参考文献

[1] Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B.B., et al. (2022) IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. Diabetes Research and Clinical Practice, 183, Article 109119. [Google Scholar] [CrossRef] [PubMed]
[2] Warburg, O. (1956) On the Origin of Cancer Cells. Science, 123, 309-314. [Google Scholar] [CrossRef] [PubMed]
[3] Chandel, N.S. (2021) Glycolysis. Cold Spring Harbor Perspectives in Biology, 13, a040535. [Google Scholar] [CrossRef] [PubMed]
[4] Lunt, S.Y. and Vander Heiden, M.G. (2011) Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation. Annual Review of Cell and Developmental Biology, 27, 441-464. [Google Scholar] [CrossRef] [PubMed]
[5] Cordani, M., Michetti, F., Zarrabi, A., Zarepour, A., Rumio, C., Strippoli, R., et al. (2024) The Role of Glycolysis in Tumorigenesis: From Biological Aspects to Therapeutic Opportunities. Neoplasia, 58, Article 101076. [Google Scholar] [CrossRef] [PubMed]
[6] Pelicano, H., Martin, D.S., Xu, R. and Huang, P. (2006) Glycolysis Inhibition for Anticancer Treatment. Oncogene, 25, 4633-4646. [Google Scholar] [CrossRef] [PubMed]
[7] Liu, Y., Xu, R., Gu, H., Zhang, E., Qu, J., Cao, W., et al. (2021) Metabolic Reprogramming in Macrophage Responses. Biomarker Research, 9, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
[8] Jing, C., Castro-Dopico, T., Richoz, N., Tuong, Z.K., Ferdinand, J.R., Lok, L.S.C., et al. (2020) Macrophage Metabolic Reprogramming Presents a Therapeutic Target in Lupus Nephritis. Proceedings of the National Academy of Sciences, 117, 15160-15171. [Google Scholar] [CrossRef] [PubMed]
[9] Madai, S., Kilic, P., Schmidt, R.M., Bas-Orth, C., Korff, T., Büttner, M., et al. (2024) Activation of the Hypoxia-Inducible Factor Pathway Protects against Acute Ischemic Stroke by Reprogramming Central Carbon Metabolism. Theranostics, 14, 2856-2880. [Google Scholar] [CrossRef] [PubMed]
[10] Adler, A., Bennett, P., Chair, S.C., Gregg, E., Venkat Narayan, K.M., Schmidt, M.I., et al. (2021) WITHDRAWN: Reprint of: Classification of Diabetes Mellitus. Diabetes Research and Clinical Practice, Article 108972. [Google Scholar] [CrossRef] [PubMed]
[11] Rabbani, N., Xue, M. and Thornalley, P.J. (2022) Hexokinase-2-Linked Glycolytic Overload and Unscheduled Glycolysis—Driver of Insulin Resistance and Development of Vascular Complications of Diabetes. International Journal of Molecular Sciences, 23, Article 2165. [Google Scholar] [CrossRef] [PubMed]
[12] Haythorne, E., Lloyd, M., Walsby-Tickle, J., Tarasov, A.I., Sandbrink, J., Portillo, I., et al. (2022) Altered Glycolysis Triggers Impaired Mitochondrial Metabolism and Mtorc1 Activation in Diabetic β-Cells. Nature Communications, 13, Article No. 6754. [Google Scholar] [CrossRef] [PubMed]
[13] Nichols, C.G. and Remedi, M.S. (2012) The Diabetic β-Cell: Hyperstimulated Vs. Hyperexcited. Diabetes, Obesity and Metabolism, 14, 129-135. [Google Scholar] [CrossRef] [PubMed]
[14] Mäkinen, S., Sree, S., Ala-Nisula, T., Kultalahti, H., Koivunen, P. and Koistinen, H.A. (2024) Activation of the Hypoxia-Inducible Factor Pathway by Roxadustat Improves Glucose Metabolism in Human Primary Myotubes from Men. Diabetologia, 67, 1943-1954. [Google Scholar] [CrossRef] [PubMed]
[15] Murao, N., Yokoi, N., Takahashi, H., Hayami, T., Minami, Y. and Seino, S. (2022) Increased Glycolysis Affects β-Cell Function and Identity in Aging and Diabetes. Molecular Metabolism, 55, Article 101414. [Google Scholar] [CrossRef] [PubMed]
[16] Harold, K.M., Matsuzaki, S., Pranay, A., Loveland, B.L., Batushansky, A., Mendez Garcia, M.F., et al. (2024) Loss of Cardiac PFKFB2 Drives Metabolic, Functional, and Electrophysiological Remodeling in the Heart. Journal of the American Heart Association, 13, e033676. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, Y., Fan, M., Qian, H., Ying, H., Li, Y. and Wang, L. (2023) Whole Grains-Derived Functional Ingredients against Hyperglycemia: Targeting Hepatic Glucose Metabolism. Critical Reviews in Food Science and Nutrition, 64, 7268-7289. [Google Scholar] [CrossRef] [PubMed]
[18] Posa, D.K. and Baba, S.P. (2020) Intracellular Ph Regulation of Skeletal Muscle in the Milieu of Insulin Signaling. Nutrients, 12, Article 2910. [Google Scholar] [CrossRef] [PubMed]
[19] Umanath, K. and Lewis, J.B. (2018) Update on Diabetic Nephropathy: Core Curriculum 2018. American Journal of Kidney Diseases, 71, 884-895. [Google Scholar] [CrossRef] [PubMed]
[20] Fan, C., Yang, G., Li, C., Cheng, J., Chen, S. and Mi, H. (2025) Uncovering Glycolysis-Driven Molecular Subtypes in Diabetic Nephropathy: A WGCNA and Machine Learning Approach for Diagnostic Precision. Biology Direct, 20, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[21] Luo, Q., Liang, W., Zhang, Z., Zhu, Z., Chen, Z., Hu, J., et al. (2022) Compromised Glycolysis Contributes to Foot Process Fusion of Podocytes in Diabetic Kidney Disease: Role of Ornithine Catabolism. Metabolism, 134, Article 155245. [Google Scholar] [CrossRef] [PubMed]
[22] Yu, B., Shen, K., Li, T., Li, J., Meng, M., Liu, W., et al. (2023) Glycolytic Enzyme PFKFB3 Regulates Sphingosine 1-Phosphate Receptor 1 in Proangiogenic Glomerular Endothelial Cells under Diabetic Condition. American Journal of Physiology-Cell Physiology, 325, C1354-C1368. [Google Scholar] [CrossRef] [PubMed]
[23] Qi, W., Keenan, H.A., Li, Q., Ishikado, A., Kannt, A., Sadowski, T., et al. (2017) Pyruvate Kinase M2 Activation May Protect against the Progression of Diabetic Glomerular Pathology and Mitochondrial Dysfunction. Nature Medicine, 23, 753-762. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, Z., Zhu, Z., Liang, W., Luo, Z., Hu, J., Feng, J., et al. (2023) Reduction of Anaerobic Glycolysis Contributes to Angiotensin II-Induced Podocyte Injury with Foot Process Effacement. Kidney International, 103, 735-748. [Google Scholar] [CrossRef] [PubMed]
[25] Shopit, A., Niu, M., Wang, H., Tang, Z., Li, X., Tesfaldet, T., et al. (2020) Protection of Diabetes-Induced Kidney Injury by Phosphocreatine via the Regulation of ERK/NrF2/HO-1 Signaling Pathway. Life Sciences, 242, Article 117248. [Google Scholar] [CrossRef] [PubMed]
[26] Dillmann, W.H. (2019) Diabetic Cardiomyopathy: What Is It and Can It Be Fixed? Circulation Research, 124, 1160-1162. [Google Scholar] [CrossRef] [PubMed]
[27] Sun, Q., Karwi, Q.G., Wong, N. and Lopaschuk, G.D. (2024) Advances in Myocardial Energy Metabolism: Metabolic Remodeling in Heart Failure and beyond. Cardiovascular Research, 120, 1996-2016. [Google Scholar] [CrossRef] [PubMed]
[28] Da Silva, D., Ausina, P., Alencar, E.M., Coelho, W.S., Zancan, P. and Sola-Penna, M. (2012) Metformin Reverses Hexokinase and Phosphofructokinase Downregulation and Intracellular Distribution in the Heart of Diabetic Mice. IUBMB Life, 64, 766-774. [Google Scholar] [CrossRef] [PubMed]
[29] Bockus, L.B., Matsuzaki, S., Vadvalkar, S.S., Young, Z.T., Giorgione, J.R., Newhardt, M.F., et al. (2017) Cardiac Insulin Signaling Regulates Glycolysis through Phosphofructokinase 2 Content and Activity. Journal of the American Heart Association, 6, e007159. [Google Scholar] [CrossRef] [PubMed]
[30] Donthi, R.V., Ye, G., Wu, C., McClain, D.A., Lange, A.J. and Epstein, P.N. (2004) Cardiac Expression of Kinase-Deficient 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase Inhibits Glycolysis, Promotes Hypertrophy, Impairs Myocyte Function, and Reduces Insulin Sensitivity. Journal of Biological Chemistry, 279, 48085-48090. [Google Scholar] [CrossRef] [PubMed]
[31] Mansor, L.S., Mehta, K., Aksentijevic, D., Carr, C.A., Lund, T., Cole, M.A., et al. (2015) Increased Oxidative Metabolism Following Hypoxia in the Type 2 Diabetic Heart, Despite Normal Hypoxia Signalling and Metabolic Adaptation. The Journal of Physiology, 594, 307-320. [Google Scholar] [CrossRef] [PubMed]
[32] Feuvray, D. (1997) Controversies on the Sensitivity of the Diabetic Heart to Ischemic Injury: The Sensitivity of the Diabetic Heart to Ischemic Injury Is Decreased. Cardiovascular Research, 34, 113-120. [Google Scholar] [CrossRef] [PubMed]
[33] Tate, M., Higgins, G.C., De Blasio, M.J., Lindblom, R., Prakoso, D., Deo, M., et al. (2019) The Mitochondria-Targeted Methylglyoxal Sequestering Compound, Mitogamide, Is Cardioprotective in the Diabetic Heart. Cardiovascular Drugs and Therapy, 33, 669-674. [Google Scholar] [CrossRef] [PubMed]
[34] Xu, G., Zhang, J. and Tang, L. (2023) Inflammation in Diabetic Retinopathy: Possible Roles in Pathogenesis and Potential Implications for Therapy. Neural Regeneration Research, 18, 976-982. [Google Scholar] [CrossRef] [PubMed]
[35] Sabanayagam, C., Banu, R., Chee, M.L., Lee, R., Wang, Y.X., Tan, G., et al. (2019) Incidence and Progression of Diabetic Retinopathy: A Systematic Review. The Lancet Diabetes & Endocrinology, 7, 140-149. [Google Scholar] [CrossRef] [PubMed]
[36] Liu, S., Ju, Y. and Gu, P. (2022) Experiment-Based Interventions to Diabetic Retinopathy: Present and Advances. International Journal of Molecular Sciences, 23, Article 7005. [Google Scholar] [CrossRef] [PubMed]
[37] Zhang, C., Gu, L., Xie, H., Liu, Y., Huang, P., Zhang, J., et al. (2024) Glucose Transport, Transporters and Metabolism in Diabetic Retinopathy. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1870, Article 166995. [Google Scholar] [CrossRef] [PubMed]
[38] Selva, M.L., Beltramo, E., Pagnozzi, F., Bena, E., Molinatti, P.A., Molinatti, G.M., et al. (1996) Thiamine Corrects Delayed Replication and Decreases Production of Lactate and Advanced Glycation End-Products in Bovine Retinal and Human Umbilical Vein Endothelial Cells Cultured under High Glucose Conditions. Diabetologia, 39, 1263-1268. [Google Scholar] [CrossRef] [PubMed]
[39] Cai, L., Xia, M. and Zhang, F. (2024) Redox Regulation of Immunometabolism in Microglia Underpinning Diabetic Retinopathy. Antioxidants, 13, Article 423. [Google Scholar] [CrossRef] [PubMed]
[40] Rajala, A., Soni, K. and Rajala, R.V.S. (2020) Metabolic and Non-Metabolic Roles of Pyruvate Kinase M2 Isoform in Diabetic Retinopathy. Scientific Reports, 10, Article No. 7456. [Google Scholar] [CrossRef] [PubMed]
[41] Tomita, Y., Cagnone, G., Fu, Z., Cakir, B., Kotoda, Y., Asakage, M., et al. (2021) Vitreous Metabolomics Profiling of Proliferative Diabetic Retinopathy. Diabetologia, 64, 70-82. [Google Scholar] [CrossRef] [PubMed]
[42] (2019) Diabetic Neuropathy. Nature Reviews Disease Primers, 5, 42. [Google Scholar] [CrossRef] [PubMed]
[43] Fernyhough, P. (2015) Mitochondrial Dysfunction in Diabetic Neuropathy: A Series of Unfortunate Metabolic Events. Current Diabetes Reports, 15, Article No. 89. [Google Scholar] [CrossRef] [PubMed]
[44] Eid, S.A., Rumora, A.E., Beirowski, B., Bennett, D.L., Hur, J., Savelieff, M.G., et al. (2023) New Perspectives in Diabetic Neuropathy. Neuron, 111, 2623-2641. [Google Scholar] [CrossRef] [PubMed]
[45] Cheng, R., Feng, Y., Liu, D., Wang, Z., Zhang, J., Chen, L., et al. (2019) The Role of Nav1.7 and Methylglyoxal-Mediated Activation of TRPA1 in Itch and Hypoalgesia in a Murine Model of Type 1 Diabetes. Theranostics, 9, 4287-4307. [Google Scholar] [CrossRef] [PubMed]
[46] Rojas, D.R., Kuner, R. and Agarwal, N. (2019) Metabolomic Signature of Type 1 Diabetes-Induced Sensory Loss and Nerve Damage in Diabetic Neuropathy. Journal of Molecular Medicine, 97, 845-854. [Google Scholar] [CrossRef] [PubMed]
[47] Chandrasekaran, K., Najimi, N., Sagi, A.R., Yarlagadda, S., Salimian, M., Arvas, M.I., et al. (2022) NAD+ Precursors Repair Mitochondrial Function in Diabetes and Prevent Experimental Diabetic Neuropathy. International Journal of Molecular Sciences, 23, Article 4887. [Google Scholar] [CrossRef] [PubMed]
[48] Mizukami, H. and Osonoi, S. (2020) Collateral Glucose-Utlizing Pathwaya in Diabetic Polyneuropathy. International Journal of Molecular Sciences, 22, Article 94. [Google Scholar] [CrossRef] [PubMed]
[49] Aghanoori, M., Margulets, V., Smith, D.R., Kirshenbaum, L.A., Gitler, D. and Fernyhough, P. (2021) Sensory Neurons Derived from Diabetic Rats Exhibit Deficits in Functional Glycolysis and ATP That Are Ameliorated by IGF-1. Molecular Metabolism, 49, Article 101191. [Google Scholar] [CrossRef] [PubMed]
[50] Dal Canto, E., Ceriello, A., Rydén, L., Ferrini, M., Hansen, T.B., Schnell, O., et al. (2019) Diabetes as a Cardiovascular Risk Factor: An Overview of Global Trends of Macro and Micro Vascular Complications. European Journal of Preventive Cardiology, 26, 25-32. [Google Scholar] [CrossRef] [PubMed]
[51] Li, W., Xu, H., Hu, Y., He, P., Ni, Z., Xu, H., et al. (2013) Edaravone Protected Human Brain Microvascular Endothelial Cells from Methylglyoxal-Induced Injury by Inhibiting AGEs/RAGE/Oxidative Stress. PLOS ONE, 8, e76025. [Google Scholar] [CrossRef] [PubMed]
[52] Kırça, M. and Yeşilkaya, A. (2021) Methylglyoxal Stimulates Endoplasmic Reticulum Stress in Vascular Smooth Muscle Cells. Journal of Receptors and Signal Transduction, 42, 279-284. [Google Scholar] [CrossRef] [PubMed]
[53] Vannucci, S.J., Willing, L.B., Goto, S., Alkayed, N.J., Brucklacher, R.M., Wood, T.L., et al. (2001) Experimental Stroke in the Female Diabetic, db/db, Mouse. Journal of Cerebral Blood Flow & Metabolism, 21, 52-60. [Google Scholar] [CrossRef] [PubMed]
[54] Yadav, D., Yadav, A., Bhattacharya, S., Dagar, A., Kumar, V. and Rani, R. (2024) GLUT and HK: Two Primary and Essential Key Players in Tumor Glycolysis. Seminars in Cancer Biology, 100, 17-27. [Google Scholar] [CrossRef] [PubMed]
[55] Vogt, B., Mühlbacher, C., Carrascosa, J., Obermaier-Kusser, B., Seffer, E., Mushack, J., et al. (1992) Subcellular Distribution of GLUT 4 in the Skeletal Muscle of Lean Type 2 (Non-Insulin-Dependent) Diabetic Patients in the Basal State. Diabetologia, 35, 456-463. [Google Scholar] [CrossRef] [PubMed]
[56] Gaudreault, N., Scriven, D.R.L. and Moore, E.D.W. (2004) Characterisation of Glucose Transporters in the Intact Coronary Artery Endothelium in Rats: GLUT-2 Upregulated by Long-Term Hyperglycaemia. Diabetologia, 47, 2081-2092. [Google Scholar] [CrossRef] [PubMed]
[57] Rashid, K., Das, J. and Sil, P.C. (2013) Taurine Ameliorate Alloxan Induced Oxidative Stress and Intrinsic Apoptotic Pathway in the Hepatic Tissue of Diabetic Rats. Food and Chemical Toxicology, 51, 317-329. [Google Scholar] [CrossRef] [PubMed]
[58] Kasai, D., Adachi, T., Deng, L., Nagano-Fujii, M., Sada, K., Ikeda, M., et al. (2009) HCV Replication Suppresses Cellular Glucose Uptake through Down-Regulation of Cell Surface Expression of Glucose Transporters. Journal of Hepatology, 50, 883-894. [Google Scholar] [CrossRef] [PubMed]
[59] Zhao, F., Deng, J., Yu, X., Li, D., Shi, H. and Zhao, Y. (2015) Protective Effects of Vascular Endothelial Growth Factor in Cultured Brain Endothelial Cells against Hypoglycemia. Metabolic Brain Disease, 30, 999-1007. [Google Scholar] [CrossRef] [PubMed]
[60] Nopparat, C., Chaopae, W., Boontem, P., Sopha, P., Wongchitrat, P. and Govitrapong, P. (2022) Melatonin Attenuates High Glucose-Induced Changes in Beta Amyloid Precursor Protein Processing in Human Neuroblastoma Cells. Neurochemical Research, 47, 2568-2579. [Google Scholar] [CrossRef] [PubMed]
[61] Ganapathy-Kanniappan, S. and Geschwind, J.H. (2013) Tumor Glycolysis as a Target for Cancer Therapy: Progress and Prospects. Molecular Cancer, 12, Article No. 152. [Google Scholar] [CrossRef] [PubMed]
[62] Trus, M.D., Zawalich, W.S., Burch, P.T., Berner, D.K., Weill, V.A. and Matschinsky, F.M. (1981) Regulation of Glucose Metabolism in Pancreatic Islets. Diabetes, 30, 911-922. [Google Scholar] [CrossRef] [PubMed]
[63] Rabbani, N., Xue, M. and Thornalley, P.J. (2022) Hexokinase-2-Linked Glycolytic Overload and Unscheduled Glycolysis—Driver of Insulin Resistance and Development of Vascular Complications of Diabetes. International Journal of Molecular Sciences, 23, Article 2165. [Google Scholar] [CrossRef] [PubMed]
[64] Rabbani, N. and Thornalley, P.J. (2024) Hexokinase-Linked Glycolytic Overload and Unscheduled Glycolysis in Hyperglycemia-Induced Pathogenesis of Insulin Resistance, Beta-Cell Glucotoxicity, and Diabetic Vascular Complications. Frontiers in Endocrinology, 14, Article 1268308. [Google Scholar] [CrossRef] [PubMed]
[65] Rabbani, N. and Thornalley, P.J. (2019) Hexokinase-2 Glycolytic Overload in Diabetes and Ischemia-Reperfusion Injury. Trends in Endocrinology & Metabolism, 30, 419-431. [Google Scholar] [CrossRef] [PubMed]
[66] Silva, D.D., Zancan, P., Coelho, W.S., Gomez, L.S. and Sola-Penna, M. (2010) Metformin Reverses Hexokinase and 6-Phosphofructo-1-Kinase Inhibition in Skeletal Muscle, Liver and Adipose Tissues from Streptozotocin-Induced Diabetic Mouse. Archives of Biochemistry and Biophysics, 496, 53-60. [Google Scholar] [CrossRef] [PubMed]
[67] Li, J., Liu, H., Takagi, S., Nitta, K., Kitada, M., Srivastava, S.P., et al. (2020) Renal Protective Effects of Empagliflozin via Inhibition of EMT and Aberrant Glycolysis in Proximal Tubules. JCI Insight, 5, e129034. [Google Scholar] [CrossRef] [PubMed]
[68] Nederlof, R., Eerbeek, O., Hollmann, M.W., Southworth, R. and Zuurbier, C.J. (2014) Targeting Hexokinase II to Mitochondria to Modulate Energy Metabolism and Reduce Ischaemia-Reperfusion Injury in Heart. British Journal of Pharmacology, 171, 2067-2079. [Google Scholar] [CrossRef] [PubMed]
[69] Xia, F., Sun, J., Jiang, Y. and Li, C. (2018) MicroRNA-384-3p Inhibits Retinal Neovascularization through Targeting Hexokinase 2 in Mice with Diabetic Retinopathy. Journal of Cellular Physiology, 234, 721-730. [Google Scholar] [CrossRef] [PubMed]
[70] Islam, M.T., Khan, M.A.A.M., Rahman, S. and Kibria, K.M.K. (2024) Genetic Association of Novel SNPs in HK-1 (rs201626997) and HK-3 (rs143604141) with Type 2 Diabetes Mellitus in Bangladeshi Population. Gene, 914, Article 148409. [Google Scholar] [CrossRef] [PubMed]
[71] Malkki, M., Laakso, M. and Deeb, S.S. (1994) Structure of the Human Hexokinase II Gene. Biochemical and Biophysical Research Communications, 205, 490-496. [Google Scholar] [CrossRef] [PubMed]
[72] Mali, A.V., Bhise, S.S., Hegde, M.V. and Katyare, S.S. (2016) Altered Erythrocyte Glycolytic Enzyme Activities in Type-II Diabetes. Indian Journal of Clinical Biochemistry, 31, 321-325. [Google Scholar] [CrossRef] [PubMed]
[73] Mendez Garcia, M.F., Matsuzaki, S., Batushansky, A., Newhardt, R., Kinter, C., Jin, Y., et al. (2023) Increased Cardiac PFK-2 Protects against High-Fat Diet-Induced Cardiomyopathy and Mediates Beneficial Systemic Metabolic Effects. iScience, 26, Article 107131. [Google Scholar] [CrossRef] [PubMed]
[74] Amadi, P.U., Osuoha, J.O., Ekweogu, C.N., Jarad, S.J., Efiong, E.E., Odika, P.C., et al. (2025) Phenolic Acids from Anisopus mannii Modulates Phosphofructokinase 1 to Improve Glycemic Control in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Clinical Trial. Pharmacological Research, 212, Article 107602. [Google Scholar] [CrossRef] [PubMed]
[75] Schoors, S., De Bock, K., Cantelmo, A.R., Georgiadou, M., Ghesquière, B., Cauwenberghs, S., et al. (2014) Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis. Cell Metabolism, 19, 37-48. [Google Scholar] [CrossRef] [PubMed]
[76] Martins, C.P., New, L.A., O’Connor, E.C., Previte, D.M., Cargill, K.R., Tse, I.L., et al. (2021) Glycolysis Inhibition Induces Functional and Metabolic Exhaustion of CD4+ T Cells in Type 1 Diabetes. Frontiers in Immunology, 12, Article 669456. [Google Scholar] [CrossRef] [PubMed]
[77] Agius, L., Ford, B.E. and Chachra, S.S. (2020) The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective. International Journal of Molecular Sciences, 21, Article 3240. [Google Scholar] [CrossRef] [PubMed]
[78] Zhang, Z., Deng, X., Liu, Y., Liu, Y., Sun, L. and Chen, F. (2019) PKM2, Function and Expression and Regulation. Cell & Bioscience, 9, Article No. 52. [Google Scholar] [CrossRef] [PubMed]
[79] Gassaway, B.M., Cardone, R.L., Padyana, A.K., Petersen, M.C., Judd, E.T., Hayes, S., et al. (2019) Distinct Hepatic PKA and CDK Signaling Pathways Control Activity-Independent Pyruvate Kinase Phosphorylation and Hepatic Glucose Production. Cell Reports, 29, 3394-3404.E9. [Google Scholar] [CrossRef] [PubMed]
[80] Nakatsu, D., Horiuchi, Y., Kano, F., Noguchi, Y., Sugawara, T., Takamoto, I., et al. (2015) L-Cysteine Reversibly Inhibits Glucose-Induced Biphasic Insulin Secretion and ATP Production by Inactivating PKM2. Proceedings of the National Academy of Sciences, 112, E1067-E1076. [Google Scholar] [CrossRef] [PubMed]
[81] Liu, H., Takagaki, Y., Kumagai, A., Kanasaki, K. and Koya, D. (2020) The PKM2 Activator TEPP-46 Suppresses Kidney Fibrosis via Inhibition of the EMT Program and Aberrant Glycolysis Associated with Suppression of Hif‐1α Accumulation. Journal of Diabetes Investigation, 12, 697-709. [Google Scholar] [CrossRef] [PubMed]
[82] Sharma, D., Singh, M. and Rani, R. (2022) Role of LDH in Tumor Glycolysis: Regulation of LDHA by Small Molecules for Cancer Therapeutics. Seminars in Cancer Biology, 87, 184-195. [Google Scholar] [CrossRef] [PubMed]
[83] Yang, P., Xu, W., Liu, L. and Yang, G. (2023) Association of Lactate Dehydrogenase and Diabetic Retinopathy in US Adults with Diabetes Mellitus. Journal of Diabetes, 16, e13476. [Google Scholar] [CrossRef] [PubMed]
[84] Tang, L., Yang, Q., Ma, R., Zhou, P., Peng, C., Xie, C., et al. (2024) Association between Lactate Dehydrogenase and the Risk of Diabetic Kidney Disease in Patients with Type 2 Diabetes. Frontiers in Endocrinology, 15, Article 1369968. [Google Scholar] [CrossRef] [PubMed]
[85] Zhao, L., Dong, M., Ren, M., Li, C., Zheng, H. and Gao, H. (2018) Metabolomic Analysis Identifies Lactate as an Important Pathogenic Factor in Diabetes-Associated Cognitive Decline Rats. Molecular & Cellular Proteomics, 17, 2335-2346. [Google Scholar] [CrossRef] [PubMed]
[86] Adki, K.M. and Kulkarni, Y.A. (2022) Paeonol Attenuates Retinopathy in Streptozotocin-Induced Diabetes in Rats by Regulating the Oxidative Stress and Polyol Pathway. Frontiers in Pharmacology, 13, Article 891485. [Google Scholar] [CrossRef] [PubMed]
[87] Wu, M., Ye, W., Zheng, Y. and Zhang, S. (2017) Oxamate Enhances the Anti-Inflammatory and Insulin-Sensitizing Effects of Metformin in Diabetic Mice. Pharmacology, 100, 218-228. [Google Scholar] [CrossRef] [PubMed]

为你推荐